Lumen Bioscience, Inc.
Seattle, WA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1441 N 34th St #300, Seattle, WA 98103, USA
- Website
- lumen.bio
- Founded
- 2017
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $3,000,000 |
| FY2024 | $748,025 |
| FY2023 | $4,430,498 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Panacea | Office of the Secretary of Defense | $8,178,523 | |
| Lumen bioscience, INC. Intranasal antibody cocktail delivery platform AOI #6 beyond the needle | Office of the Assistant Secretary for Preparedness and Response | $703,000 |
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Trustees Of Boston University | 75A50122C00028 | $1,065,478 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| University Of Washington | UC2DK126006 | $210,788 | |
| University Of Washington | UC2DK126006 | $190,378 |
Similar vendors
About the company
Lumen Bioscience Inc. is a biotechnology company that specializes in synthesizing high-value products using a novel platform organism. Through federal contracts and grants, Lumen Bioscience provides biological research and development services, including developing biologic drugs and therapeutic delivery platforms.
Lumen Bioscience has received prime federal contracts to provide an intranasal antibody cocktail delivery platform to the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, supporting mitigation of long-term respiratory distress. As a subcontractor, Lumen Bioscience is developing an oral vaccine candidate to prevent diarrheal diseases caused by C. jejuni and Enterotoxigenic E. coli for the Trustees of Boston University.
Through federal grants, Lumen Bioscience is conducting a Phase 2/3 clinical trial investigating an anti-infective therapeutic to treat and prevent C. difficile infection, funded by the Defense Health Agency's Military Medical Research and Development program. Lumen Bioscience also received a Department of Energy grant to develop alkaline carbon capture and expression-streamlined Spirulina cultivated in air for reliable bioproducts, oil and nutrition. As a subgrantee, Lumen Bioscience is delivering novel therapies to enhance and repair glomerular regeneration for the University of Washington, and developing an oral vaccine candidate to prevent C. jejuni and Enterotoxigenic E. coli diarrheal diseases for the Trustees of Boston University.
Quick answers
Is Lumen Bioscience, Inc. registered in SAM.gov?
Yes. Lumen Bioscience, Inc.'s SAM.gov registration is active through December 18, 2026.
What is Lumen Bioscience, Inc.'s CAGE code?
Lumen Bioscience, Inc.'s CAGE code is 7UBN7, and its Unique Entity ID (UEI) is E9UJDT3BFUQ5.
How much has Lumen Bioscience, Inc. received in federal contracts?
Federal contracts obligated $3,000,000 to Lumen Bioscience, Inc. in fiscal year 2025 and $8,178,523 in fiscal years 2023 through 2027.
What is Lumen Bioscience, Inc.'s most recent federal award?
Lumen Bioscience, Inc.'s most recent federal grant award is A phase 2/3, randomized, double-blind, placebo-controlled study of LMN-201 for treatment and prevention of C. Difficile… (HT94252310959), from Defense Health Agency, on September 15, 2023.
On GovTribe
See Lumen Bioscience, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors